Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1077-1085

  Wong, Nan Soon ^a   Anderson, Benjamin O ^b   Khoo, Kei Siong ^c   Ang, Peng Tiam ^c   Yip, Cheng Har ^d   Lu, Yen Shen ^e   Voravud, Narind ^f   Shao, Zhi Ming ^g   Pritchard, Kathleen I ^h  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g Cancer Hospital   (China)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB;

ADJUVANT THERAPY; ASIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COST; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEART DEATH; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW;

ANTINEOPLASTIC AGENTS; ASIA; BREAST NEOPLASMS; CONGRESSES AS TOPIC; DEVELOPING COUNTRIES; DRUG COSTS; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 71549153340     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70230-X     Document Type: Review

References (89)

1. In: Stewart B.W., and Kleihues P. (Eds). World Cancer Report (2003), IARC Press, Lyon
2. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
3. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
4. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase 3 randomized trial. J Clin Oncol 19 (2001) 3808-3816
5. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
6. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 (2007) 1496-1506
7. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
8. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (1996) 737-744
9. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
11. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
12. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
13. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
14. Slamon D, Eiermann W, Robert N, et al. Phase 3 randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th San Antonio Breast Symposium; San Antonio, TX, USA; Dec 8-11, 2005; abstr 1.
15. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
16. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 113 (2008) 2221-2243
17. Di Leo A., Gomez H., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer. J Clin Oncol 26 (2008) 5544-5552
18. Wolff A., Hammond M., Schwartz J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
19. Shyyan R., Sener S.F., Anderson B.O., et al. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer 113 suppl 8 (2008) 2257-2268
20. Carlson R.W., Allred D.C., Anderson B.O., et al. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7 (2009) 122-192
21. Sauter G., Lee J., Bartlett J.M., et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27 (2009) 1323-1333
22. Bartlett J., Going J., Mallon E., et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195 (2001) 422-428
23. Jacobs T., Gown A., Yaziji H., et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 (1999) 1974-1982
24. Jacobs T., Gown A., Yaziji H., et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17 (1999) 1983-1987
25. Press M., Slamon D., Flom K., et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
26. Mass R., Press M., Anderson S., et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clinical Breast Cancer 6 (2005) 240-246
27. Elkin E., Weinstein M., Winer E., et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22 (2004) 854-863
28. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 24 (2006) 3032-3038
29. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
30. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
31. Leonard G.D., and Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96 (2004) 906-920
32. Ringberg A., Anagnostaki L., Anderson H., et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37 (2001) 1514-1522
33. Cornfield D.B., Palazzo J.P., Schwartz G.F., et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 100 (2004) 2317-2327
34. Dahabreh I.J., Linardou H., Siannis F., et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13 (2008) 620-630
35. Madarnas Y., Trudeau M., Franek J.A., et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34 (2008) 539-557
36. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
37. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25 suppl (2007) abstr 512.
38. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase 3 randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. 29th San Antonio Breast Symposium; San Antonio, TX, USA; Dec 14-17, 2006; abstr 52.
39. Spielmann M, Roché H, Humblet Y, et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. 30th San Antonio Breast Symposium; San Antonio, TX, USA; Dec 13-16, 2007; abstr 72.
40. Perez E.A., Suman V., Davidson N., et al. Further analysis of NCCTG-N9831 [slides on the Internet]. In: 2005 American Society of Clinical Oncologists virtual meeting: advances in monoclonal antibody therapy for breast cancer scientific symposium. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_ses sion_presentations_view&confID=34&trackID=1&sessionID=934 (accessed June 27, 2009).
41. Perez E.A., Suman V., Davidson N., et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22 (2004) 3700-3704
42. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
43. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23 (2005) 2900-2902
44. Jones A.L., Barlow M., Barrett-Lee P.J., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100 (2009) 684-692
45. Martín M., Esteva F.J., Alba E., et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14 (2009) 1-11
46. NCRI Breast Clinical Studies Group. UK clinical guidelines for the use of adjuvant trastuzumab (Herceptin) with or following chemotherapy in HER2-positive early breast cancer (2005). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/docu ments/digitalasset/dh_4126384.pdf (accessed June 27, 2009).
47. Coudert B.P., Largillier R., Arnould L., et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25 (2007) 2678-2684
48. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable reast cancer. J Clin Oncol 23 (2005) 3676-3685
49. Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13 (2007) 228-233
50. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 31.
51. Liberato N.L., Marchetti M., and Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25 (2007) 625-633
52. McKeage K., and Lyseng-Williamson K.A. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 26 (2008) 699-719
53. The World Bank. World Development Indicators 2009 (2009), The World Bank, Washington DC
54. Eniu A., Carlson R.W., El Saghir N.S., et al. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer 113 suppl 8 (2008) 2269-2281
55. Rakkhit R, Broglio K, Peintinger F, et al. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a, bN0M0 tumours. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 701.
56. Tovey SM, Marla S, Brown S, et al. Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours: implications for trastuzumab therapy? 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 702.
57. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
58. Jones S., Holmes F.A., O'Shaughnessy J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27 (2009) 1177-1183
59. Jones SE, Collea RP, Oratz R, et al. Preliminary toxicity results of a phase 2 trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer patients. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 2111.
60. Love R.R., Duc N.B., Havighurst T.C., et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21 (2003) 453-457
61. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 27 suppl 9 (2000) 20-26
62. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase 2 trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23 (2005) 4265-4274
63. Esteva F.J., Valero V., Booser D., et al. Phase 2 study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
64. Pegram M.D., Pienkowski T., Northfelt D.W., et al. Results of two open-label, multicenter phase 2 studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96 (2004) 759-769
65. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as firstline therapy for HER2-overexpressing metastatic breast cancer: multicenter phase 2 trial with clinical outcomes, analysis of serum tumour markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
66. Jahanzeb M., Mortimer J.E., Yunus F., et al. Phase 2 trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7 (2002) 410-417
67. Schaller G., Fuchs I., Gonsch T., et al. Phase 2 study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25 (2007) 3246-3250
68. Chia S., Clemons M., Martin L.-A., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase 2 trial. J Clin Oncol 24 (2006) 2773-2778
69. O'Shaughnessy J., Vukelja S.J., Marsland T., Kimmel G., Ratnam S., and Pippen J. Phase 2 trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 3 (2002) 17-20
70. Pegram M.D., and Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor enhanced chemosensitivity. Semin Oncol 26 (1999) 89-95
71. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase 3 study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24 (2006) 2786-2792
72. Sledge Jr. G.W. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park) 17 (2003) 33-35
73. Cortes J., Di Cosimo S., Climent M.A., et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase 1-2 study. Clin Cancer Res 15 (2009) 307-314
74. Bianchi G., Albanell J., Eiermann W., et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9 (2003) 5944-5951
75. Montemurro F., Redana S., Viale G., et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer 8 (2008) 436-442
76. Gelmon K.A., Mackey J., Verma S., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5 (2004) 52-58
77. Antoine E, Extra J, Vincent-Salomon A, et al. L. Multiple lines of trastuzumab may provide a survival benefit for women with HER2-positive metastatic breast cancer: data from the Hermine cohort study. 2007 ASCO Breast Cancer Symposium; San Francisco, CA (USA); Sept 7-8, 2007; abstr 230.
78. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27 (2009) 1999-2006
79. Lidgren M., Wilking N., Jönsson B., et al. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 47 (2008) 1018-1028
80. Elkin E.B., Weinstein M.C., Winer E.P., et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22 (2004) 854-863
81. Lin N.U., Diéras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 (2009) 1452-1459
82. Lin NU, Paul D, Dieras V, et al. Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer an updated analysis from EGF105084. 30th San Antonio Breast Symposium; San Antonio, TX, USA; Dec 13-16, 2007; abstr 6076.
83. O'Shaughnessy J., Blackwell K.L., Burstein H., et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26 suppl (2008) abstr 1015.
84. Mackay JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone dependent and HER-2 positive metastatic breast cancer. 29th San Antonio Breast Symposium; San Antonio, TX, USA; Dec 14-17, 2006; abstr 3.
85. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 46.
86. Modi S., Stopeck A.T., Gordon M.S., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase 1 dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
87. O'Regan R, Andre F, Campone M, et al. RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase 1 clinical trial. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 3119.
88. Fasolo A, Gianni L, Rorive A, et al. Multicenter phase 1 clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. 31st San Antonio Breast Symposium; San Antonio, TX, USA; Dec 10-14, 2008; abstr 406.
89. Bontenbal M., Seynaeve C., Stouthard J., et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study). J Clin Oncol 26 suppl (2008) abstr 1014.